Choline alfoscerate (Cholitilin) 400 mg – [56 capsules]

Choline alphoscerate, is a cholinomimetic of central action with predominant influence on the central nervous system.

The drug contains 40.5% choline, which is released from the compound in the brain; choline is involved in the biosynthesis of acetylcholine (one of the main mediators of nerve excitation). Alphoscerate is biotransformed to glycerophosphate, which is a precursor of phospholipids.

Acetylcholine has a positive effect on nerve impulse transmission, and glycerophosphate participates in the synthesis of phosphatidylcholine (a membrane phospholipid), resulting in improved membrane elasticity and receptor function.

Choline alphoscerate enhances metabolic processes and activates structures of the reticular formation of the brain.

It has a preventive and corrective effect on factors of involutional psychoorganic syndrome, such as changes in the phospholipid composition of neuronal membranes and decreased cholinergic activity. Pharmacodynamic studies have shown that choline alphoscerate acts on synaptic, including cholinergic transmission of nerve impulse (neurotransmission), neuronal membrane plasticity and receptor function.

– Impaired cerebral circulation of the ischemic type (acute and recovery periods) and hemorrhagic type (recovery period).

– Psycho-organic syndrome against the background of involutionary and degenerative processes of the brain.

– Consequences of cerebrovascular insufficiency or primary and secondary cognitive disorders in the elderly, characterized by memory impairment, confusion, disorientation, decreased motivation and initiative, reduced concentration of attention.

– Behavioral and affective disorders in old age: emotional lability, increased irritability, decreased interest; senile pseudomelancholy.

– Multi-infarct dementia.

Contraindications .

– Hypersensitivity to the components of Choline alfoscerate (Cholitilin) 400 mg.

– Pregnancy.

– Breast-feeding period.

– Children under 18 years old (for lack of data).

Administration during pregnancy and breast feeding period.

Usage of the Choline alfoscerate (Cholitilin) 400 mg is contraindicated during pregnancy and breastfeeding.